Paradoxical reduction in pancreatic glucagon with normalization of somatostatin and decrease in insulin in normoglycemic alloxan-diabetic dogs: a putative mechanism of glucagon irresponsiveness to hypoglycemia
- PMID: 1967577
- DOI: 10.1210/endo-126-2-1096
Paradoxical reduction in pancreatic glucagon with normalization of somatostatin and decrease in insulin in normoglycemic alloxan-diabetic dogs: a putative mechanism of glucagon irresponsiveness to hypoglycemia
Abstract
In alloxan-diabetic (A-D) dogs, plasma glucagon does not increase when glycemia is decreased by insulin. Therefore, as in insulin-dependent diabetes mellitus (IDDM), increased glucose utilization is not matched by an increase in hepatic production. To explore further the abnormal effects of insulin on regulation of pancreatic glucagon, we studied content and morphology of pancreatic hormones in six normal (N) dogs, five hyperglycemic A-D (HD) dogs, and in four A-D dogs where normoglycemia was maintained by insulin (ND). Morphometric measurement of islets and of immunocytochemically localized A cells (glucagon) were performed by an image analysis system. In normal pancreas, islets of tail and body were bigger in size (tail = 4850 +/- 376 microns 2, body = 3256 +/- 198 microns 2), than the head (2009 +/- 207 microns 2). Glucagon content was 331 +/- 50 micrograms with a mean concentration of 8.5 +/- 0.9 micrograms/g in N dogs, and did not change in HD dogs (422 +/- 34 micrograms, 9.3 +/- 0.4 micrograms/g). With normoglycemia, glucagon content decreased by 5-fold (p less than 0.001). Morphometry indicated that, although A cell area per islet increased (2.7-fold), islet number decreased (70%), explaining the unchanged glucagon content in HD dogs. This decrease in islet number can also justify the dramatic glucagon decrease in ND dogs. Despite the 70% decrease in islet numbers in HD dogs, pancreatic somatostatin increased 3-fold (9.93 +/- 3.3 to 30.6 +/- 7.2 micrograms), indicating that its islet content was augmented 10-fold. Somatostatin content returned to normal with normoglycemia. Pancreatic insulin content in HD dogs was negligible (55 +/- 23 micrograms) when compared with that in N dogs (5500 micrograms) and it did not increase with normoglycemia. The distinct but markedly diminished insulin and proinsulin peaks in HD dogs nearly disappeared in ND dogs. Thus, in alloxan-diabetic HD dogs, 70% of islets are destroyed. A marked increase in glucagon in residual islets can explain the unchanged islet size despite the absence of B cells; however, the percent increase of somatostatin is larger than that of glucagon. Normoglycemia 1) normalizes somatostatin content, 2) further diminishes insulin and proinsulin synthesis presumably due to lack of hyperglycemic stimulus, and 3) paradoxically decreases pancreatic glucagon content 5-fold below its normal level. We hypothesize that with normalization of plasma insulin, glucagon content in each islet normalizes, but because of destruction of most islets, pancreatic glucagon content becomes extremely low.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Increase in somatostatin to glucagon ratio in islets of alloxan-diabetic dogs: effect of insulin-induced euglycemia.Can J Physiol Pharmacol. 1993 Jul;71(7):512-7. doi: 10.1139/y93-074. Can J Physiol Pharmacol. 1993. PMID: 7902197
-
Elevated somatostatin in pancreatic islets of adrenalectomized dogs.Endocrinology. 1987 Feb;120(2):544-8. doi: 10.1210/endo-120-2-544. Endocrinology. 1987. PMID: 2879722
-
Changes in somatostatin concentration in pancreas and other tissues of streptozotocin diabetic rats.Endocrinology. 1978 Sep;103(3):917-23. doi: 10.1210/endo-103-3-917. Endocrinology. 1978. PMID: 154402
-
Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction.Adv Exp Med Biol. 2010;654:421-45. doi: 10.1007/978-90-481-3271-3_18. Adv Exp Med Biol. 2010. PMID: 20217508 Review.
-
Effect of stress on glucoregulation in physiology and diabetes.Adv Exp Med Biol. 1991;291:161-83. doi: 10.1007/978-1-4684-5931-9_13. Adv Exp Med Biol. 1991. PMID: 1927681 Review.
Cited by
-
Amelioration of hypoglycemia via somatostatin receptor type 2 antagonism in recurrently hypoglycemic diabetic rats.Diabetes. 2013 Jul;62(7):2215-22. doi: 10.2337/db12-1523. Epub 2013 Feb 22. Diabetes. 2013. PMID: 23434929 Free PMC article.
-
Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats.Diabetes. 2012 Jan;61(1):197-207. doi: 10.2337/db11-0690. Epub 2011 Nov 21. Diabetes. 2012. PMID: 22106159 Free PMC article.
-
Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.Endocrinology. 2021 Dec 1;162(12):bqab189. doi: 10.1210/endocr/bqab189. Endocrinology. 2021. PMID: 34477204 Free PMC article.
-
Glucagon secretion and signaling in the development of diabetes.Front Physiol. 2012 Sep 4;3:349. doi: 10.3389/fphys.2012.00349. eCollection 2012. Front Physiol. 2012. PMID: 22969729 Free PMC article.
-
RNA-Seq Analysis of Abdominal Fat in Genetically Fat and Lean Chickens Highlights a Divergence in Expression of Genes Controlling Adiposity, Hemostasis, and Lipid Metabolism.PLoS One. 2015 Oct 7;10(10):e0139549. doi: 10.1371/journal.pone.0139549. eCollection 2015. PLoS One. 2015. PMID: 26445145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical